OUr pipeline
program
Indication
Target(s)
Discovery
Lead Optimization
IND enabling
phase 1
RNDO-564
Bladder Cancer and other Solid Tumors
CD28 x Nectin-4
RNDO-Program 2
Ovarian
CD3 x Undisclosed CD28 x Undisclosed
RNDO-Program 3
Endometrial
CD3 x CD28 x Undisclosed
RNDO-Program 4
Renal
CD3 x CD28 x Undisclosed
Undisclosed
Undisclosed
RNDO-564
RNDO-Program 2
RNDO-Program 3
RNDO-Program 4
BlaDDER CANCER
Bladder cancer represents approximately 6% of all cancer diagnoses in the United States. Among patients with muscle-invasive disease, up to half experience disease progression or metastasis following surgery, and five-year survival rates remain below 10%.
The introduction of Nectin-4-targeting antibody-drug conjugates (ADCs) and checkpoint inhibitor combinations has improved outcomes, yet durability of response remains limited and treatment-related toxicities often constrain long-term use.
RNDO-564, Rondo’s lead clinical-stage candidate, is a fully human CD28 × Nectin-4 bispecific antibody designed to safely deliver tumor-localized co-stimulation.
By optimizing the Nectin-4 binding arm and calibrating the CD28 arm for controlled activation, RNDO-564 focuses immune stimulation within the tumor microenvironment.
This approach aims to sustain T-cell activity, enhance durability of response, and broaden the therapeutic window for the treatment of bladder cancer.
OVARIAN
Most ovarian cancer is diagnosed at an advanced stage. Although current therapies, including chemotherapy, PARP inhibitors, and ADCs, often yield strong initial responses, disease recurrence is common and typically incurable. Five-year survival rates remain poor, highlighting the urgent need for innovative immunotherapeutic strategies.
RNDO-Program 2 features two novel bispecific antibodies: CD3 x TAA-1 and CD28 x TAA-2 – each targeting a distinct tumor-associated antigen (TAA).
By integrating T-cell activation and co-stimulation within the tumor microenvironment, this approach aims to elicit robust, localized immune responses while minimizing systemic toxicity.
